NEWRON PHARMACEUT. EO-20 risk profile
47 Elevated one input has moved against it
Measured 21 October 2026 from NP5's filed statements. Recomputed nightly.
47 (Elevated), driven by Leverage and coverage at 97, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 85 | Acute | Volatile | One-year price volatility — 66.0% |
| Operating pressure | 44 | Elevated | Worsening | Costs outgrowing revenue — +57.3 percentage points |
| Cash conversion | 11 | Contained | Easing | Capital spending against operating cash — 0.00x |
| Leverage and coverage | 97 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 34 | Normal | Stable | Operating-margin gap against peers — -12.7 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for NEWRON PHARMACEUT. EO-20